Display Settings:

Format

Send to:

Choose Destination
    Ophthalmol Clin North Am. 2002 Dec;15(4):529-36, viii.

    Cytomegalovirus retinitis in the era of combined highly active antiretroviral therapy.

    Source

    Department of Ophthalmology, Doheny Eye Institute, Keck School of Medicine, University of Southern California, 1450 San Pablo Street, DVRC 211, Los Angeles, CA 90033, USA.

    Abstract

    Advancements in antiretroviral therapy have changed the way we view and treat cytomegalovirus retinitis (CMVR). At one time the diagnosis of CMVR necessitated that most patients undergo daily intravenous infusions of anti-CMV agents. Today, after the restoration of their immune systems, they are able to stop maintenance anti-CMV therapy. HAART failure, resistant strains of CMV, and immune recovery uveitis are growing challenges.

    PMID:
    12515085
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk